About US
Contact us
-
DSM Announces License Agreement with Amgen for Use of DSM's XD® Cell Culture PatentsDSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a non-exclusive license agreement with Amgen I2013/1/21
-
Pfizer's Bosulif set for greater sales with EMA approvalPfizer ($PFE) has extended the run of good news for its focus on targeted cancer treatment with a positive recommendation from EU regulators for Bosulif. The nod sets the stage for another approval a2013/1/21
-
Drugmakers beware, Costco now in pharmacy benefitsIn the evolving drug payer world, pharmacy benefit managers (PBM) are commanding a bigger role. Now drug companies have a new and interesting PBM with which to contend--Costco. The discounter has s2013/1/18
-
Additional testing completed on Alzheimer's disease biomarkerBiopharma company Navidea Biopharmaceuticals has announced the completion of a study into its new radiopharmaceutical NAV4694, which is designed to be used as a biomarker for visual detection of subs2013/1/18
-
EU signs off on Lilly's Amyvid, its diagnostic test for Alzheimer'sWhile Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, t2013/1/17
-
Armed with diagnostic, Biogen files for first-line Tysabri useIf persistence is a virtue, then Biogen Idec ($BIIB) is about as virtuous as they come. After years of safety problems, warnings, testing and retesting, the company has asked U.S. and European authori2013/1/17
-
Generic Reglan user can sue Pfizer for damagesIt's a state court ruling. It directly affects only one drugmaker. But the Alabama Supreme Court's decision to allow a patient to sue Pfizer ($PFE) for damages could ripple through the industry--and2013/1/15
-
Patients laud Lundbeck, Gilead, but give pharma's rep low marksPatients aren't happy with the pharma industry. A drumbeat of bad pharma news in 2012 took its toll on public opinion to the point where only one-third of patient groups gave drugmakers a thumbs-up.2013/1/15
-
India to hit Roche, BMS with compulsory licenses on 3 cancer drugsIndia is taking another swipe at Big Pharma. Three swipes, in fact: The government has started the process of granting three more compulsory licenses, this time on cancer treatments from Roche ($RHHB2013/1/14
-
Wockhardt receives approval for generic epilepsy tabletsWockhardt has announced the receipt of final approval for the marketing of a generic form of Lamotrigine, a form of medication which is used to treat epilepsy. The pharmaceutical and biotechnology2013/1/14